MarketCapExport financials
Agilent Technologies (A)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Agilent Technologies Income Statement 2025-2006 | A
Brief overview of income trends at Agilent Technologies
The conclusions below are based on five years of reported results. Agilent Technologies reported revenue of $5.3 billion in 2020 and $6.9 billion by 2025. The cumulative result was +30.1%, corresponding to roughly 5.4% per year. This represents moderate business growth.
Gross profit changed from $2.8 billion to $3.6 billion (+28.4%). There was no major divergence between sales and cost of revenue. The gross margin was 53.1% at the start and 52.4% at the end. Gross profitability remained broadly stable.
Over the period, EBITDA shifted from 1.2 billion dollars to 1.8 billion dollars, a change of +53.1%. Additional revenue translated efficiently into EBITDA. At the operating-margin level, the figure shifted from 21.6% to 25.4%. The increased EBITDA share is a positive sign.
The five-year change in net income was +81.2%: from 719 million dollars to 1.3 billion dollars. The period finished with its strongest net-income result.
The market value of the business moved from 36 billion dollars to 31.5 billion dollars, or −12.4%. Capitalization grew more slowly than the underlying results.
What the figures show
Most key measures improved without a pronounced weak signal. The positive side is supported by sales growth, consistent sales economics and an improving EBITDA margin. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Agilent Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
31.5 B | 38.1 B | 34.2 B | 36.8 B | 42 B | 36 B | 25.4 B | 23.2 B | 22.3 B | 14.3 B | 13.9 B | 14.2 B | 13.1 B | 9.53 B | 9.31 B | 7.81 B | 4.67 B | 9.58 B | 10.8 K | - |
Shares |
284 M | 290 M | 294 M | 299 M | 304 M | 308 M | 314 M | 321 M | 322 M | 326 M | 333 M | 333 M | 341 M | 348 M | 347 M | 347 M | 346 M | 363 M | 394 | - |
Historical Prices |
111 | 131 | 116 | 123 | 139 | 119 | 81.2 | 74.1 | 70.9 | 46.8 | 35.6 | 35.4 | 38.6 | 29.4 | 27.7 | 22.5 | 13.5 | 26.4 | 27.4 | 25.1 |
Net Income |
1.3 B | 1.29 B | 1.24 B | 1.25 B | 1.21 B | 719 M | 1.07 B | 316 M | 684 M | 462 M | 401 M | 504 M | 724 M | 1.15 B | 1.01 B | 684 M | -31 M | 693 M | 638 M | - |
Revenue |
6.95 B | 6.51 B | 6.83 B | 6.85 B | 6.32 B | 5.34 B | 5.16 B | 4.91 B | 4.47 B | 4.2 B | 4.04 B | 6.98 B | 6.78 B | 6.86 B | 6.62 B | 5.44 B | 4.48 B | - | - | - |
Cost of Revenue |
3.3 B | 2.98 B | 3.37 B | 3.13 B | 2.91 B | 2.5 B | 2.36 B | 2.23 B | 2.06 B | 2 B | 2 B | 3.39 B | 3.25 B | 3.25 B | 3.09 B | 2.51 B | 2.19 B | 2.58 B | 2.45 B | - |
Gross Profit |
- | - | - | - | - | 2.84 B | 2.8 B | 2.69 B | 2.41 B | 2.2 B | 2.04 B | 3.59 B | 3.54 B | 3.6 B | 3.53 B | - | - | - | - | - |
Operating Income |
1.48 B | 1.49 B | 1.35 B | 1.62 B | 1.35 B | 846 M | 941 M | 904 M | 807 M | 615 M | 522 M | 419 M | 386 M | 1.12 B | 1.07 B | 566 M | 47 M | 795 M | 584 M | - |
Interest Expense |
112 M | 96 M | 95 M | 84 M | 81 M | 78 M | 74 M | 75 M | 79 M | 72 M | 66 M | 110 M | 107 M | 101 M | 86 M | 96 M | 88 M | 123 M | 5 M | - |
EBITDA |
1.77 B | 1.74 B | 1.62 B | 1.94 B | 1.67 B | 1.15 B | 1.18 B | 1.14 B | 1.05 B | 861 M | 775 M | 1.22 B | 1.32 B | 1.42 B | 1.32 B | 768 M | 209 M | 996 M | 775 M | - |
Operating Expenses |
- | - | - | - | - | 1.99 B | 1.86 B | 1.76 B | 1.57 B | 1.58 B | 1.52 B | 2.76 B | 2.58 B | 2.48 B | 2.46 B | - | - | - | - | - |
General and Administrative Expenses |
1.71 B | 1.57 B | 1.63 B | 1.64 B | 1.62 B | 1.5 B | 1.46 B | 1.37 B | 1.23 B | 1.25 B | 1.19 B | 2.04 B | 1.88 B | 1.82 B | 1.81 B | 1.75 B | 1.6 B | 1.7 B | 1.7 B | - |
All numbers in USD currency
Quarterly Income Statement Agilent Technologies
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
282 M | 283 M | 283 M | 283 M | 284 M | 285 M | 285 M | 285 M | 290 M | 293 M | 293 M | 294 M | 296 M | 296 M | 301 M | 295 M | - | 299 M | 306 M | 302 M | 303 M | 304 M | 310 M | 309 M | 309 M | 309 M | 318 M | 316 M | 312 M | 317 M | 323 M | 322 M | 320 M | 322 M | 322 M | 322 M | 321 M | 321 M | 329 M | 326 M | 325 M | 326 M | 336 M | 334 M | 332 M | 334 M | 333 M | 333 M | 334 M | 333 M | 347 M | 344 M | 339 M | 345 M | 348 M | 348 M | 348 M | 348 M | 347 M | 347 M | 348 M | 347 M | 347 M | 348 | 348 | 345 M |
Net Income |
339 M | 305 M | 305 M | - | 336 M | 318 M | 318 M | - | 282 M | 348 M | 348 M | 111 M | 302 M | 302 M | 283 M | - | - | 274 M | 288 M | - | 264 M | 216 M | 197 M | 497 M | 199 M | 101 M | 504 M | 877 M | 191 M | 182 M | -320 M | 121 M | 236 M | 205 M | 168 M | 507 M | 175 M | 164 M | 121 M | 336 M | 124 M | 91 M | 63 M | 261 M | 111 M | 87 M | 195 M | 481 M | 147 M | 139 M | 179 M | 513 M | 168 M | 166 M | 230 M | 728 M | 243 M | 255 M | 193 M | 723 M | 330 M | 200 M | 205 M | 108 M | 79 M | -19 M |
Revenue |
1.84 B | 1.8 B | 1.8 B | - | 1.74 B | 1.68 B | 1.68 B | - | 1.58 B | 1.66 B | 1.66 B | 1.67 B | 1.72 B | 1.72 B | 1.67 B | - | - | 1.61 B | 1.55 B | - | 1.59 B | 1.52 B | 1.36 B | 3.86 B | 1.26 B | 1.24 B | 1.28 B | 3.8 B | 1.27 B | 1.24 B | 1.21 B | 3.62 B | 1.2 B | 1.21 B | 1.07 B | 3.28 B | 1.11 B | 1.1 B | 1.03 B | 3.09 B | 1.04 B | 1.02 B | 1.03 B | 3 B | 1.01 B | 963 M | 1.01 B | 3 B | 1.01 B | 988 M | 1.68 B | 5.06 B | 1.65 B | 1.73 B | 1.64 B | 5.09 B | 1.72 B | 1.73 B | 1.52 B | 4.89 B | 1.69 B | 1.68 B | - | - | - | - |
Cost of Revenue |
845 M | 852 M | 852 M | - | 850 M | 782 M | 782 M | - | 723 M | 750 M | 750 M | 1.01 B | 793 M | 793 M | 764 M | - | - | 746 M | 710 M | - | 734 M | 708 M | 634 M | 1.81 B | 592 M | 581 M | 577 M | 1.73 B | 582 M | 569 M | 538 M | 1.65 B | 542 M | 562 M | 493 M | 1.52 B | 518 M | 510 M | 491 M | 1.48 B | 502 M | 489 M | 513 M | 1.5 B | 501 M | 483 M | 498 M | 1.51 B | 507 M | 503 M | 800 M | 2.44 B | 796 M | 841 M | 761 M | 2.41 B | 833 M | 815 M | 703 M | 2.28 B | 799 M | 777 M | 659 M | 560 M | 553 M | 518 M |
Operating Income |
399 M | 353 M | 353 M | - | 360 M | 376 M | 376 M | - | 333 M | 384 M | 384 M | 133 M | 383 M | 383 M | 376 M | - | - | 360 M | 328 M | - | 336 M | 288 M | 215 M | 547 M | 230 M | 102 M | 250 M | 691 M | 225 M | 216 M | 229 M | 660 M | 221 M | 210 M | 206 M | 608 M | 201 M | 201 M | 155 M | 432 M | 146 M | 131 M | 115 M | 366 M | 144 M | 107 M | 124 M | 349 M | 131 M | 94 M | 217 M | 666 M | 236 M | 213 M | 271 M | 841 M | 270 M | 300 M | 211 M | 758 M | 281 M | 266 M | 115 M | 154 M | 94 M | -1 M |
Interest Expense |
25 M | 25 M | 25 M | - | 28 M | 28 M | 28 M | - | 22 M | 22 M | 22 M | 24 M | 24 M | 24 M | 21 M | - | - | 21 M | 19 M | - | 21 M | 20 M | 20 M | 59 M | 19 M | 20 M | 18 M | 53 M | 18 M | 17 M | 20 M | 57 M | 18 M | 19 M | 20 M | 59 M | 19 M | 20 M | 18 M | 53 M | 17 M | 18 M | 16 M | 50 M | 17 M | 17 M | 29 M | 87 M | 28 M | 30 M | 25 M | 77 M | 27 M | 25 M | 26 M | 75 M | 24 M | 25 M | 23 M | 63 M | 20 M | 20 M | 24 M | 22 M | 9 M | -24 M |
EBITDA |
533 M | 420 M | 420 M | - | 386 M | 448 M | 448 M | - | 358 M | 446 M | 446 M | 342 M | 521 M | 421 M | 458 M | - | - | 411 M | 404 M | - | 489 M | 333 M | 294 M | 779 M | 385 M | 149 M | 304 M | 853 M | 332 M | 242 M | 280 M | 814 M | 322 M | 236 M | 261 M | 768 M | 310 M | 233 M | 221 M | 622 M | 276 M | 171 M | 183 M | 559 M | 275 M | 145 M | 220 M | 640 M | 324 M | 143 M | 311 M | 943 M | 422 M | 263 M | 333 M | 1.05 B | 393 M | 326 M | 274 M | 948 M | 408 M | 297 M | 250 M | 229 M | 133 M | 121 M |
General and Administrative Expenses |
465 M | 476 M | 476 M | - | 417 M | 410 M | 410 M | - | 395 M | 396 M | 396 M | 407 M | 415 M | 415 M | 417 M | - | - | 386 M | 407 M | - | 403 M | 420 M | 404 M | 1.11 B | 347 M | 358 M | 355 M | 1.08 B | 366 M | 354 M | 347 M | 1.03 B | 341 M | 341 M | 289 M | 904 M | 308 M | 307 M | 304 M | 932 M | 310 M | 318 M | 310 M | 892 M | 290 M | 292 M | 298 M | 887 M | 285 M | 304 M | 484 M | 1.43 B | 449 M | 497 M | 441 M | 1.35 B | 458 M | 452 M | 446 M | 1.36 B | 449 M | 469 M | 456 M | 407 M | 417 M | 387 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Agilent Technologies (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
CareDx, Inc
CDNA
|
$ 54.31 | 0.32 % | $ 2.89 B |  USA |
 |
Celcuity
CELC
|
$ 79.99 | 0.12 % | $ 3.74 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.88 | 0.09 % | $ 1.01 B | USA |
 |
Danaher Corporation
DHR
|
$ 221.56 | 0.21 % | $ 158 B | USA |
 |
DexCom
DXCM
|
$ 87.73 | 0.21 % | $ 34.2 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 21.27 | 0.51 % | $ 655 M | USA |
 |
Guardant Health
GH
|
$ 176.31 | 0.27 % | $ 22.1 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 163.9 | 0.2 % | $ 12.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 522.02 | 0.1 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
$ 267.86 | 0.41 % | $ 46 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.75 | 3.33 % | $ 89.2 K | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 303.98 | 0.09 % | $ 25.3 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 99.97 | 0.01 % | $ 6.75 B | USA |
 |
Medpace Holdings
MEDP
|
$ 617.15 | 0.23 % | $ 17.8 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 492.34 | 0.11 % | $ 30.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 4.01 | 0.62 % | $ 371 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 6.5 | 4.33 % | $ 5.12 M | USA |
 |
NeoGenomics
NEO
|
$ 18.36 | 0.03 % | $ 2.35 B | USA |
 |
Neogen Corporation
NEOG
|
$ 13.57 | 2.72 % | $ 2.95 B | USA |
 |
Natera
NTRA
|
$ 390.79 | 0.41 % | $ 53.4 B | USA |
 |
Biomerica
BMRA
|
$ 2.61 | 0.36 % | $ 7.61 M | USA |
 |
OPKO Health
OPK
|
$ 1.7 | 0.29 % | $ 1.28 B | USA |
 |
RadNet
RDNT
|
$ 73.21 | 0.11 % | $ 5.5 B | USA |
 |
Sotera Health Company
SHC
|
$ 18.29 | 0.45 % | $ 5.19 B | USA |
 |
Neuronetics
STIM
|
$ 2.88 | 0.21 % | $ 190 M | USA |
 |
Trinity Biotech plc
TRIB
|
$ 7.01 | 0.68 % | $ 2.52 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 158.47 | 0.93 % | $ 9.48 B | USA |
 |
Biodesix
BDSX
|
$ 29.29 | 4.05 % | $ 221 M | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.25 | 2.99 % | $ 31.4 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 420.57 | 0.52 % | $ 25 B | USA |
 |
Exagen
XGN
|
$ 8.55 | 1.39 % | $ 184 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.7 | 0.55 % | $ 9.26 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 15.08 | 11.68 % | $ 162 M |  China |
 |
Bioventus
BVS
|
$ 13.61 | 2.55 % | $ 907 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 13.45 | 0.88 % | $ 457 M | Israel |